Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IWR-1 |
Synonyms | |
Therapy Description |
IWR-1 selectively inhibits Wnt/beta-catenin mediated signaling by inhibiting tankyrase1/2, thus stabilizing Axin and stimulating beta-catenin degradation (PMID: 23621985, PMID: 31452704). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IWR-1 | IWR-1-endo | Tankyrase Inhibitor 11 | IWR-1 selectively inhibits Wnt/beta-catenin mediated signaling by inhibiting tankyrase1/2, thus stabilizing Axin and stimulating beta-catenin degradation (PMID: 23621985, PMID: 31452704). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC S1197* APC S1278* | colorectal cancer | sensitive | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481). | 28179481 |
APC L665* APC R1450* | colorectal cancer | sensitive | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481). | 28179481 |
APC R216* | colorectal cancer | sensitive | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481). | 28179481 |
APC I1164fs | colorectal cancer | sensitive | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481). | 28179481 |
APC N1819fs | colorectal cancer | resistant | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481). | 28179481 |
APC S811* | colorectal cancer | sensitive | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481). | 28179481 |
APC E853* APC T1556fs | colorectal cancer | resistant | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481). | 28179481 |
APC W553* | colorectal cancer | sensitive | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481). | 28179481 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|